Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

Conditions

• HIV Infections
• Fatty Liver Disease

Interventions

• DRUG: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day
• DRUG: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day
• DRUG: Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.

Sponsor

Fundacion SEIMC-GESIDA